KRYS vs PATH · P/E 46, rev $290.5M vs P/E 19, rev $1.61B
Krystal Biotech Inc (KRYS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported KRYS revenue for 2024-12-31 was $290.5M. Net income was $89.2M. Revenue was up 473.0% from 2023-12-31 to 2024-12-31. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
KRYS currently screens at market cap $10.17B and trailing P/E 46.1. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the KRYS and PATH stock pages for the full models.
Not investment advice.